Monday , 24 June 2024

Consensus Clinical Recommendations for the Management of Dyslipidaemia in the African Population

1Ndjessan Jean Jacques, 2Ekou Arnaud, 3Boka Benedicte, 4Amelie Delphine Lagou, 5Ake Traboulsi, 6Adoubi Anicet, 7Ngoran Yves, 8Kadio Ede Martin, 9Angoran Ines, 10Dago Koffi, 11Traore Diabey Fatoumata, 12Kacou JbAnzouan,13*Shalini Kumar, 14Isha Desai Mistry, 15Pravin Joshi
1Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
2Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
3Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
4Nephrologist,The University Hospital Center of Bouake,Ivory Coast
5Cardiologist,PISAM Hospital, Abidjan,Ivory Coast
6Cardiologist, The University Hospital Center of Bouake,Ivory Coast
7Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
8Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
9Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
10Endocrinologist,The University Hospital Center of  Cocody, Ivory Coast
11Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
12Cardiologist, Institute of Cardiology, Abidjan, Ivory Coast
13Ajanta Pharma, Mumbai, India
14Ajanta Pharma, Mumbai, India
15Ajanta Pharma, Mumbai, India

A B S T R A C T
Context: While there are many international guidelines on the management of dyslipidaemia, there is lack of clinical recommendations for the management of dyslipidaemia in the African population, considering its increasing prevalence and unique regional disparities.Objective: The objective of this consensus document was to provide original recommendations on dyslipidaemia management and to find gaps in the treatment and opportunities for improved lipid control for the population of Ivory Coast, West Africa.Design: A multidisciplinary panel of regional experts was convened and reached an original consensus on the clinical management of dyslipidaemia in the African population in February 2023.Method:A panel of 12 experts in the fields of cardiology, endocrinology, and nephrology was formed from Ivory Coast, West Africa. The panel discussed a questionnaire based on existing guidelines. Recommendations were constructed in accordance with local and regional clinical practices. Results: The panel made recommendations on the diagnosis and management of dyslipidaemia in patients at risk for diabetes and cardiovascular disease in the Ivory Coast population. Atorvastatin was recommended as a high-intensity statin to reduce low-density lipoprotein cholesterol by more than 50% of clinicians. Additionally, recommendations were made on statin therapy in patients with atherosclerotic cardiovascular disease, diabetes, and chronic kidney disease. Conclusion: Regional practitioners, in addition to adhering to dyslipidaemia-management guidelines, need to consider dietary and lifestyle behaviours when formulating management strategies for dyslipidaemia. Clinicians must work with patients to create customised therapies. Greater consensus among regional experts across Africa can create a unified approach for the entire region.

Keywords: dyslipidaemia, clinical recommendations, cardiology, endocrinology, nephrology, Atorvastatin

Scroll To Top